Personal information

No personal information available

Activities

Employment (5)

Apellis Pharmaceuticals (United States): Waltham, Massachusetts, US

2021-08-31 to present | Associate Director Complement Science (Discovery)
Employment
Source: Self-asserted source
Martin Kolev

GlaxoSmithKline Research & Development Limited: Stevenage, Hertfordshire, GB

2018-05-30 to 2021-08-30 | Scientific Investigator (Research Unit)
Employment
Source: Self-asserted source
Martin Kolev

National Institutes of Health: Bethesda, MD, US

2017-10-01 to 2018-02-28 | Visiting scholar (Complement and inflammation research section)
Employment
Source: Self-asserted source
Martin Kolev

King's College London: London, London, GB

2012-06-12 to 2017-06-12 | Post doctoral researcer (DTIMB)
Employment
Source: Self-asserted source
Martin Kolev

Cardiff University: Cardiff, Cardiff, GB

2008-03-01 to 2008-09-31 | Research Assistant (Infection and Immunity)
Employment
Source: Self-asserted source
Martin Kolev

Education and qualifications (3)

Cardiff University: Cardiff, Cardiff, GB

2008-10-01 to 2012-03-01 | PhD (Infection and Immunity)
Education
Source: Self-asserted source
Martin Kolev

Sofia University Saint Kliment Ohridski Department of Sociology: Sofia, BG

2003-10-01 to 2005-05-01 | MSc, Biochemistry (Biology)
Education
Source: Self-asserted source
Martin Kolev

Sofia University Saint Kliment Ohridski Department of Sociology: Sofia, BG

1999-10-01 to 2003-05-01 | BSc, Molecular Biology (Biology)
Education
Source: Self-asserted source
Martin Kolev

Works (31)

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors

International Journal of Molecular Sciences
2024-08 | Journal article | Author
Contributors: Peter Hillmen; Regina Horneff; Michael Yeh; Martin Kolev; Pascal Deschatelets
Source: check_circle
Multidisciplinary Digital Publishing Institute

With complements: C3 inhibition in the clinic

Immunological Reviews
2022-09-25 | Review | Author
Part of ISSN: 0105-2896
Part of ISSN: 1600-065X
Contributors: Martin Kolev; Tara Barbour; Scott Baver; Cedric Francois; Pascal Deschatelets
Source: Self-asserted source
Martin Kolev

Inside-Out of Complement in Cancer

Frontiers in Immunology
2022-07-01 | Review
Part of ISSN: 1664-3224
Contributors: Martin Kolev; Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M. Markiewski
Source: Self-asserted source
Martin Kolev

Mitochondrial C5aR1 activity in macrophages controls IL-1β production underlying sterile inflammation.

Science immunology
2021-12-24 | Journal article
Source: Self-asserted source
Martin Kolev

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.

Science immunology
2021-04-01 | Journal article
Source: Self-asserted source
Martin Kolev

Diapedesis-Induced Integrin Signaling via LFA-1 Facilitates Tissue Immunity by Inducing Intrinsic Complement C3 Expression in Immune Cells.

Immunity
2020-03-01 | Journal article
Source: Self-asserted source
Martin Kolev

Asparaginyl Endopeptidase (Legumain) Supports Human Th1 Induction via Cathepsin L-Mediated Intracellular C3 Activation.

Frontiers in immunology
2018-10-24 | Journal article
Source: Self-asserted source
Martin Kolev

Complement and the Regulation of T Cell Responses.

Annual review of immunology
2018-04-01 | Journal article
Source: Self-asserted source
Martin Kolev

Targeting complement-mediated immunoregulation for cancer immunotherapy.

Seminars in immunology
2018-02-15 | Journal article
Source: Self-asserted source
Martin Kolev

Keeping It All Going-Complement Meets Metabolism.

Frontiers in immunology
2017 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Human plasma C3 is essential for the development of memory B, but not T, lymphocytes.

The Journal of allergy and clinical immunology
2017-11-04 | Journal article
Source: Self-asserted source
Martin Kolev

Intracellular complement - the complosome - in immune cell regulation.

Molecular immunology
2017-09 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses.

Immunity
2015-06 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Detection of CD59 using flow cytometry.

Methods in molecular biology (Clifton, N.J.)
2014 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Detection of cell membrane-bound CD46 using flow cytometry.

Methods in molecular biology (Clifton, N.J.)
2014 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Functional analysis of CD59 using complement-dependent cytotoxicity assay.

Methods in molecular biology (Clifton, N.J.)
2014 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Complement--tapping into new sites and effector systems.

Nature reviews. Immunology
2014-12 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation.

Nucleic acids research
2014-02 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.

Immunity
2013-12 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

The role of complement in CD4⁺ T cell homeostasis and effector functions.

Seminars in immunology
2013-02 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Complement in cancer and cancer immunotherapy.

Archivum immunologiae et therapiae experimentalis
2011-12 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Retraction. Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms.

Journal of immunology (Baltimore, Md. : 1950)
2011-12 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms.

Journal of immunology (Baltimore, Md. : 1950)
2010-06 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation.

Nucleic acids research
2010-05 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.

The pharmacogenomics journal
2010-02 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Neuronal death in Alzheimer's disease and therapeutic opportunities.

Journal of cellular and molecular medicine
2009 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment.

Immunology
2009-06 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Implication of complement system and its regulators in Alzheimer's disease.

Current neuropharmacology
2009-03 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity.

Journal of immunology (Baltimore, Md. : 1950)
2009-03 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q.

Biochemistry
2006-08 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central

Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains.

Biochemistry
2006-04 | Journal article
Source: Self-asserted source
Martin Kolev via Europe PubMed Central